Literature DB >> 18657584

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

Rong Xu1, Shakuntala Megati, Vidia Roopchand, Amara Luckay, Amjed Masood, Dorys Garcia-Hand, Margherita Rosati, David B Weiner, Barbara K Felber, George N Pavlakis, Maninder K Sidhu, John H Eldridge, Michael A Egan.   

Abstract

The effectiveness of plasmid DNA (pDNA) vaccines can be improved by the co-delivery of plasmid-encoded molecular adjuvants. We evaluated pDNAs encoding GM-CSF, Flt-3L, IL-12 alone, or in combination, for their relative ability to serve as adjuvants to augment humoral and cell-mediated immune responses elicited by prototype pDNA vaccines. In Balb/c mice we found that co-administration of plasmid-based murine GM-CSF (pmGM-CSF), murine Flt-3L (pmFlt-3L) or murine IL-12 (pmIL-12) could markedly enhance the cell-mediated immune response elicited by an HIV-1 env pDNA vaccine. Plasmid mGM-CSF also augmented the immune response elicited by DNA vaccines expressing HIV-1 Gag and Nef-Tat-Vif. In addition, the use of pmGM-CSF as a vaccine adjuvant appeared to markedly increase antigen-specific proliferative responses and improved the quality of the resulting T-cell response by increasing the percentage of polyfunctional memory CD8(+) T cells. Co-delivery of pmFlt-3L with pmGM-CSF did not result in a further increase in adjuvant activity. However, the co-administration of pmGM-CSF with pmIL-12 did significantly enhance env-specific proliferative responses and vaccine efficacy in the murine vaccinia virus challenge model relative to mice immunized with the env pDNA vaccine adjuvanted with either pmGM-CSF or pmIL-12 alone. These data support the testing of pmGM-CSF and pmIL-12, used alone or in combination, as plasmid DNA vaccine adjuvants in future macaque challenge studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657584      PMCID: PMC9036319          DOI: 10.1016/j.vaccine.2008.06.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   4.169


  52 in total

Review 1.  DNA vaccines for viral diseases.

Authors:  J J Donnelly; J B Ulmer
Journal:  Braz J Med Biol Res       Date:  1999-02       Impact factor: 2.590

2.  Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag.

Authors:  Jian-Tai Qiu; Ting-Chang Chang; Cheng-Tao Lin; Yi-Ming Chen; Frank Q Li; Yung-Kuei Soong; Chyong-Huey Lai
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

3.  Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.

Authors:  S Gurunathan; L Stobie; C Prussin; D L Sacks; N Glaichenhaus; A Iwasaki; D J Fowell; R M Locksley; J T Chang; C Y Wu; R A Seder
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor.

Authors:  M R Sadaie; J Rappaport; T Benter; S F Josephs; R Willis; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.

Authors:  Michael A Egan; Shakuntala Megati; Vidia Roopchand; Dorys Garcia-Hand; Amara Luckay; Siew-Yen Chong; Margherita Rosati; Solomon Sackitey; David B Weiner; Barbara K Felber; George N Pavlakis; Zimra R Israel; John H Eldridge; Maninder K Sidhu
Journal:  Vaccine       Date:  2005-08-19       Impact factor: 3.641

6.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

Authors:  M L Disis; H Bernhard; F M Shiota; S L Hand; J R Gralow; E S Huseby; S Gillis; M A Cheever
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

7.  Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Authors:  Amara Luckay; Maninder K Sidhu; Rune Kjeken; Shakuntala Megati; Siew-Yen Chong; Vidia Roopchand; Dorys Garcia-Hand; Rashed Abdullah; Ralph Braun; David C Montefiori; Margherita Rosati; Barbara K Felber; George N Pavlakis; Iacob Mathiesen; Zimra R Israel; John H Eldridge; Michael A Egan
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

8.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.

Authors:  E F Fynan; R G Webster; D H Fuller; J R Haynes; J C Santoro; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe.

Authors:  Cornelia Trimble; Cheng-Tao Lin; Chien-Fu Hung; Sara Pai; Jeremy Juang; Liangmei He; Maura Gillison; Drew Pardoll; Lee Wu; T-C Wu
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.

Authors:  Melissa L Precopio; Michael R Betts; Janie Parrino; David A Price; Emma Gostick; David R Ambrozak; Tedi E Asher; Daniel C Douek; Alexandre Harari; Giuseppe Pantaleo; Robert Bailer; Barney S Graham; Mario Roederer; Richard A Koup
Journal:  J Exp Med       Date:  2007-05-29       Impact factor: 14.307

View more
  25 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Authors:  Rashmi Jalah; Vainav Patel; Viraj Kulkarni; Margherita Rosati; Candido Alicea; Brunda Ganneru; Agneta von Gegerfelt; Wensheng Huang; Yongjun Guan; Kate E Broderick; Niranjan Y Sardesai; Celia LaBranche; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

4.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

Review 5.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

6.  Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Authors:  Nicola Winstone; Aaron J Wilson; Gavin Morrow; Cesar Boggiano; Maria J Chiuchiolo; Mary Lopez; Marina Kemelman; Arielle A Ginsberg; Karl Mullen; John W Coleman; Chih-Da Wu; Sandeep Narpala; Ian Ouellette; Hansi J Dean; Feng Lin; Niranjan Y Sardesai; Holly Cassamasa; Dawn McBride; Barbara K Felber; George N Pavlakis; Alan Schultz; Michael G Hudgens; C Richter King; Timothy J Zamb; Christopher L Parks; Adrian B McDermott
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

7.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

8.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

9.  Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant.

Authors:  Jiani Du; Xiaoyu Wu; Fengying Long; Jiejun Wen; Wenli Hao; Ran Chen; Xiaobo Kong; Min Qian; Wenzheng Jiang
Journal:  Viral Immunol       Date:  2013-01-18       Impact factor: 2.257

10.  Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice.

Authors:  Gregory G Simon; Yongli Hu; Asif M Khan; Jingshi Zhou; Jerome Salmon; Priya R Chikhlikar; Keun-Ok Jung; Ernesto T A Marques; J Thomas August
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.